Oridonin suppresses gastric cancer SGC ‐7901 cell proliferation by targeting the TNF ‐alpha/androgen receptor/ TGF ‐beta signalling pathway axis
Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. O...
Saved in:
Published in | Journal of cellular and molecular medicine Vol. 27; no. 18; pp. 2661 - 2674 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley & Sons, Inc
01.09.2023
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called
Rabdosia rubescens
(Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF‐alpha/Androgen receptor/TGF‐beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC‐7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF‐α/Androgen receptor/TGF‐β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF‐α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF‐β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC‐7901 cells by regulating the TNF‐α /AR /TGF‐β signalling pathway axis. |
---|---|
AbstractList | Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF-alpha/Androgen receptor/TGF-beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC-7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF-α/Androgen receptor/TGF-β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF-α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF-β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC-7901 cells by regulating the TNF-α /AR /TGF-β signalling pathway axis.Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF-alpha/Androgen receptor/TGF-beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC-7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF-α/Androgen receptor/TGF-β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF-α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF-β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC-7901 cells by regulating the TNF-α /AR /TGF-β signalling pathway axis. Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF-alpha/Androgen receptor/TGF-beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC-7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF-α/Androgen receptor/TGF-β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF-α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF-β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC-7901 cells by regulating the TNF-α /AR /TGF-β signalling pathway axis. Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb called Rabdosia rubescens (Hemsl.) H.Hara, has been used by local residents for the treatment of digestive tract cancer for hundreds of years. Oridonin, the main ingredient of the herb, has a curative effect for gastric cancer, but the mechanism has not been previously clarified. This study mainly aimed to investigate the role of TNF‐alpha/Androgen receptor/TGF‐beta signalling pathway axis in mediating the proliferation inhibition of oridonin on gastric cancer SGC‐7901 cells. MTT assay, cell morphology observation assay and fluorescence assay were adopted to study the efficacy of oridonin on cell proliferation. The network pharmacology was used to predict the pathway axis regulated by oridonin. Western blot assay was adopted to verify the TNF‐α/Androgen receptor/TGF‐β signalling pathway axis regulation on gastric cancer by oridonin. The results showed Oridonin could inhibit the proliferation of gastric cancer cells, change cell morphology and cause cell nuclear fragmentation. A total of 11signaling pathways were annotated by the network pharmacology, among them, Tumour necrosis factor alpha (TNF‐α) signalling pathway, androgen receptor (AR) signalling pathway and transforming growth factor (TGF‐β) signalling pathway account for the largest proportion. Oridonin can regulate the protein expression of the three signalling pathways, which is consistent with the results predicted by network pharmacology. These findings indicated that oridonin can inhibit the proliferation of gastric cancer SGC‐7901 cells by regulating the TNF‐α /AR /TGF‐β signalling pathway axis. |
Author | Gao, Shiyong Li, Dan Tan, Huixin |
AuthorAffiliation | 3 Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs Harbin China 2 Department of Pharmacy Fourth Affiliated Hospital of Harbin Medicine University Harbin China 1 Drug Engineering and Technology Research Center Harbin University of Commerce Harbin China |
AuthorAffiliation_xml | – name: 1 Drug Engineering and Technology Research Center Harbin University of Commerce Harbin China – name: 2 Department of Pharmacy Fourth Affiliated Hospital of Harbin Medicine University Harbin China – name: 3 Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs Harbin China |
Author_xml | – sequence: 1 givenname: Shiyong orcidid: 0000-0002-8499-9485 surname: Gao fullname: Gao, Shiyong organization: Drug Engineering and Technology Research Center Harbin University of Commerce Harbin China, Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs Harbin China – sequence: 2 givenname: Huixin surname: Tan fullname: Tan, Huixin organization: Department of Pharmacy Fourth Affiliated Hospital of Harbin Medicine University Harbin China – sequence: 3 givenname: Dan surname: Li fullname: Li, Dan organization: Drug Engineering and Technology Research Center Harbin University of Commerce Harbin China, Heilongjiang Provincial Key Laboratory of Tumor Prevention and Antitumor Drugs Harbin China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37431884$$D View this record in MEDLINE/PubMed |
BookMark | eNptks9u1DAQxiNURP_AhQdAlrggpO3GsRM7J1St6IJU0QPL2XLsSdarxA62A-yNR-DEA_IkONstggpfxtL85pvPnjnPTqyzkGXPcX6J01nu1DBcYsYpfpSd4ZIXC1oTenK8Y074aXYewi7PSYVJ_SQ7JYwSzDk9y37eeqOdNRaFaRw9hAABdTJEbxRS0irw6ON6hX59_8HqHCMFfY9G73rTgpfROIuaPYrSdxCN7VDcAtp8uJ552Y9buZRWe9eBRR4UjNH5JdqsD_kGokTBdFb2_Vw6yrj9KvdIfjPhafa4lX2AZ8d4kX26frtZvVvc3K7fr65uFormLC4Aawpl22gmC6KZVqTlALIkUDYVFBo0aZSuFMNclzoFUuRaU8YKxijWNbnI3tzpjlMzgFZgo5e9GL0ZpN8LJ434N2PNVnTui8A5rWlRk6Tw6qjg3ecJQhSDCfMvSQtuCqLgJaUkL_Hc7OUDdOcmn54_U1WyVnFaJOrF35b-eLmfWQLyO0B5F4KHVigTD6NIDk2frIl5LcS8FuKwFqnk9YOSe9X_wL8BZHq-Uw |
CitedBy_id | crossref_primary_10_1016_j_jep_2024_119119 crossref_primary_10_1080_15384047_2024_2322206 crossref_primary_10_1016_j_intimp_2024_113935 crossref_primary_10_3389_fphar_2024_1476739 crossref_primary_10_1007_s12672_024_01281_w crossref_primary_10_1016_j_jep_2024_118586 crossref_primary_10_1007_s12672_024_01476_1 crossref_primary_10_1016_j_ejphar_2024_176656 crossref_primary_10_1007_s10811_023_03138_1 crossref_primary_10_1016_j_ymeth_2024_07_012 crossref_primary_10_3892_ol_2024_14596 crossref_primary_10_3892_ijmm_2024_5456 crossref_primary_10_2174_0118756298310340240514060824 crossref_primary_10_1016_j_prp_2024_155688 crossref_primary_10_1016_j_ijbiomac_2024_137090 crossref_primary_10_1016_j_intimp_2024_111861 crossref_primary_10_1016_j_intimp_2025_114119 crossref_primary_10_1016_j_heliyon_2024_e34297 crossref_primary_10_1016_j_phymed_2025_156436 crossref_primary_10_3892_etm_2024_12777 crossref_primary_10_1007_s11655_024_4116_7 crossref_primary_10_1016_j_jep_2023_117020 crossref_primary_10_1177_1934578X241309226 crossref_primary_10_1007_s12013_024_01294_w crossref_primary_10_2147_IJGM_S471370 crossref_primary_10_1002_fsn3_3986 crossref_primary_10_3892_ol_2024_14822 crossref_primary_10_1167_iovs_66_2_56 crossref_primary_10_1016_j_heliyon_2024_e34215 crossref_primary_10_20517_cdr_2024_101 crossref_primary_10_3892_mmr_2024_13282 crossref_primary_10_1016_j_jep_2024_117912 crossref_primary_10_1016_j_intimp_2024_112303 crossref_primary_10_1016_j_jep_2024_118001 crossref_primary_10_1111_jcmm_70032 crossref_primary_10_1016_j_ijbiomac_2024_136472 crossref_primary_10_2147_IJGM_S476647 crossref_primary_10_3389_fphar_2024_1522787 crossref_primary_10_1007_s00210_024_03238_w crossref_primary_10_2217_fon_2023_0872 crossref_primary_10_3892_or_2024_8813 crossref_primary_10_1016_j_jprot_2024_105298 crossref_primary_10_3390_biomedicines13020359 crossref_primary_10_1016_j_fitote_2024_106347 crossref_primary_10_1016_j_intimp_2024_113827 crossref_primary_10_1016_j_fitote_2024_106189 crossref_primary_10_1016_j_jep_2024_118512 crossref_primary_10_1080_15321819_2024_2360083 crossref_primary_10_1016_j_jep_2024_119200 crossref_primary_10_3892_or_2024_8808 crossref_primary_10_1016_j_intimp_2024_112296 crossref_primary_10_1016_j_intimp_2024_113462 crossref_primary_10_1007_s00210_024_02980_5 crossref_primary_10_1007_s00210_024_03652_0 |
Cites_doi | 10.1016/j.canlet.2017.10.019 10.6023/cjocx201607022 10.1038/onc.2015.133 10.4049/jimmunol.174.10.6169 10.1080/21655979.2021.2016086 10.21037/atm-21-2630 10.1155/2021/5023536 10.1016/j.omtn.2021.01.028 10.7150/jca.55929 10.1016/j.biopha.2021.111830 10.1200/JCO.21.00468 10.1172/JCI0215970 10.1186/s41065-021-00213-w 10.1016/j.intimp.2007.10.020 10.1111/jcmm.15106 10.1158/0008-5472.CAN-13-0023 10.1007/s12672-018-0336-7 10.3390/molecules25020358 10.3892/ol.2017.5751 10.1007/s00403-009-0994-y 10.3389/fphar.2019.00123 10.1002/cam4.2393 10.1016/j.ccr.2014.03.010 10.1016/j.biopha.2018.02.011 10.1002/path.5257 10.1038/nchembio.118 10.1007/s00401-002-0661-2 10.1111/eos.12387 10.3390/ijms221810030 10.3389/fbioe.2021.600579 10.1016/S0002-9440(10)62256-0 10.1080/21655979.2021.1955177 10.1186/s13058-021-01478-9 10.1021/jm401248x 10.3109/02652040903079526 10.1002/jcb.27654 10.1016/j.ijpharm.2013.03.019 10.1248/bpb.b19-00839 10.1038/nbt1007-1110 10.3390/ijms19082378 10.1039/C5NP00005J 10.1088/0957-4484/17/23/018 10.7314/APJCP.2014.15.15.6437 10.1016/j.bbadis.2021.166290 10.1016/j.biopha.2019.109667 10.1053/j.gastro.2021.04.064 10.18632/oncotarget.21880 10.1158/1541-7786.MCR-18-0558 10.5114/aoms.2018.77068 10.3892/etm.2010.145 10.1016/j.cyto.2009.08.002 10.1016/j.cellsig.2007.12.003 10.1016/j.jsps.2017.04.037 10.1016/j.cyto.2020.155066 10.1007/s10585-014-9679-9 10.1155/2021/4340950 10.1080/10837450.2021.1982966 10.3390/md14090166 10.2147/OTT.S262022 10.1007/s10517-021-05324-y 10.1097/CAD.0000000000000797 10.3892/ol.2017.6421 10.3390/ijms22147748 10.3390/ijms21197186 10.1073/pnas.080583397 10.1001/jamaoncol.2016.4975 10.1093/abbs/gmz071 10.1038/s41419-021-04177-7 10.3892/ijo.2016.3479 10.3109/10428194.2015.1061127 10.1016/j.bbrc.2019.04.011 10.1016/j.canlet.2013.11.019 10.1111/j.1755-148X.2008.00450.x 10.1016/j.jhep.2021.06.016 10.1200/JCO.21.01983 |
ContentType | Journal Article |
Copyright | 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. – notice: 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. |
DBID | AAYXX CITATION NPM 3V. 7QP 7TK 7X7 7XB 88E 88I 8AO 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U RC3 7X8 5PM |
DOI | 10.1111/jcmm.17841 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Proquest Medical Database Science Database Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
DocumentTitleAlternate | Gao et al |
EISSN | 1582-4934 |
EndPage | 2674 |
ExternalDocumentID | PMC10494293 37431884 10_1111_jcmm_17841 |
Genre | Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: Outstanding Young Talents Project of the Central Government's Fund for Local Universities' Reform and Development grantid: 2020YQ12 – fundername: 2021 Harbin University of Commerce Teacher "Innovation" Project grantid: LH2021H002; – fundername: General Project of Education Department of Heilongjiang Province grantid: 12541571 – fundername: Natural Science Foundation in Heilongjiang Province grantid: LH2021H002 – fundername: Science and Technology Project of Heilongjiang Provincial Health and Family Planning Commission grantid: 2017-132 – fundername: Outstanding Young Talents Project of the Central Government's Fund for Local Universities’ Reform and Development grantid: 2020YQ12 – fundername: Science and Technology Project of Heilongjiang Provincial Health and Family Planning Commission grantid: 2017‐132 |
GroupedDBID | --- 0R~ 1OC 24P 29K 31~ 36B 4.4 53G 5GY 5VS 7X7 8-0 8-1 88E 88I 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AAHHS AAYXX AAZKR ABJNI ABUWG ACCFJ ACCMX ACGFS ACGOD ACXQS ADBBV ADKYN ADPDF ADRAZ ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFKRA AFZJQ AHMBA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CAG CCPQU CITATION COF CS3 D-9 D-I DIK DU5 DWQXO E3Z EBD EBS EJD EMB EMOBN F5P FYUFA GNUQQ GODZA GROUPED_DOAJ HCIFZ HMCUK HYE HZ~ IAO IHR ITC KQ8 LH4 LK8 LW6 M1P M2P M48 M7P O9- OIG OK1 OVD OVEED PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO Q2X RNS ROL RPM SV3 TEORI UKHRP NPM WIN 3V. 7QP 7TK 7XB 8FD 8FK AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U RC3 7X8 5PM |
ID | FETCH-LOGICAL-c407t-e1d4e5fbd7a23d7dc3f8eea53e5b6e2ded3bcd6c718d5dc71320dd47727741d93 |
IEDL.DBID | M48 |
ISSN | 1582-1838 1582-4934 |
IngestDate | Thu Aug 21 18:36:27 EDT 2025 Tue Aug 05 10:26:46 EDT 2025 Wed Aug 13 06:13:02 EDT 2025 Wed Feb 19 02:22:19 EST 2025 Thu Apr 24 22:58:16 EDT 2025 Tue Jul 01 01:35:22 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 18 |
Keywords | oridonin AR signalling pathway TGF-β signalling pathway gastric cancer TNF-α signalling pathway |
Language | English |
License | 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c407t-e1d4e5fbd7a23d7dc3f8eea53e5b6e2ded3bcd6c718d5dc71320dd47727741d93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Shiyong Gao and Huixin Tan should be considered joint first author. Shiyong Gao and Huixin Tan contributed equally. |
ORCID | 0000-0002-8499-9485 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1111/jcmm.17841 |
PMID | 37431884 |
PQID | 2863206842 |
PQPubID | 2034150 |
PageCount | 14 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10494293 proquest_miscellaneous_2854430519 proquest_journals_2863206842 pubmed_primary_37431884 crossref_citationtrail_10_1111_jcmm_17841 crossref_primary_10_1111_jcmm_17841 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-09-01 |
PublicationDateYYYYMMDD | 2023-09-01 |
PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Chichester – name: Hoboken |
PublicationTitle | Journal of cellular and molecular medicine |
PublicationTitleAlternate | J Cell Mol Med |
PublicationYear | 2023 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
References | e_1_2_11_70_1 e_1_2_11_72_1 Li S (e_1_2_11_18_1) 2018; 16 e_1_2_11_32_1 e_1_2_11_55_1 Sikic D (e_1_2_11_59_1) 2021; 11 e_1_2_11_78_1 e_1_2_11_30_1 e_1_2_11_57_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_13_1 e_1_2_11_34_1 e_1_2_11_53_1 e_1_2_11_76_1 e_1_2_11_11_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_48_1 Bialek J (e_1_2_11_64_1) 2021; 11 Yang D (e_1_2_11_66_1) 2001; 61 Takahashi K (e_1_2_11_74_1) 2021; 112 e_1_2_11_60_1 e_1_2_11_81_1 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_47_1 e_1_2_11_68_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_62_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_17_1 e_1_2_11_15_1 e_1_2_11_38_1 e_1_2_11_19_1 e_1_2_11_50_1 e_1_2_11_71_1 Commission NP (e_1_2_11_2_1) 2020 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_56_1 e_1_2_11_77_1 e_1_2_11_58_1 e_1_2_11_79_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_52_1 e_1_2_11_73_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_54_1 e_1_2_11_75_1 e_1_2_11_7_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_49_1 e_1_2_11_82_1 e_1_2_11_61_1 e_1_2_11_80_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_67_1 e_1_2_11_46_1 e_1_2_11_69_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_63_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_65_1 e_1_2_11_16_1 e_1_2_11_37_1 e_1_2_11_39_1 |
References_xml | – volume-title: Pharmacopoeia of People's Republic of China (2020 Edition) year: 2020 ident: e_1_2_11_2_1 – ident: e_1_2_11_71_1 doi: 10.1016/j.canlet.2017.10.019 – ident: e_1_2_11_8_1 doi: 10.6023/cjocx201607022 – ident: e_1_2_11_70_1 doi: 10.1038/onc.2015.133 – ident: e_1_2_11_80_1 doi: 10.4049/jimmunol.174.10.6169 – ident: e_1_2_11_50_1 doi: 10.1080/21655979.2021.2016086 – ident: e_1_2_11_16_1 doi: 10.21037/atm-21-2630 – ident: e_1_2_11_29_1 doi: 10.1155/2021/5023536 – ident: e_1_2_11_58_1 doi: 10.1016/j.omtn.2021.01.028 – ident: e_1_2_11_4_1 doi: 10.7150/jca.55929 – ident: e_1_2_11_17_1 doi: 10.1016/j.biopha.2021.111830 – ident: e_1_2_11_62_1 doi: 10.1200/JCO.21.00468 – ident: e_1_2_11_77_1 doi: 10.1172/JCI0215970 – ident: e_1_2_11_72_1 doi: 10.1186/s41065-021-00213-w – ident: e_1_2_11_82_1 doi: 10.1016/j.intimp.2007.10.020 – volume: 61 start-page: 5857 issue: 15 year: 2001 ident: e_1_2_11_66_1 article-title: Murine six‐transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate‐specific membrane antigen: prostate‐specific cell‐surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice publication-title: Cancer Res – ident: e_1_2_11_19_1 doi: 10.1111/jcmm.15106 – ident: e_1_2_11_68_1 doi: 10.1158/0008-5472.CAN-13-0023 – ident: e_1_2_11_57_1 doi: 10.1007/s12672-018-0336-7 – ident: e_1_2_11_51_1 doi: 10.3390/molecules25020358 – ident: e_1_2_11_21_1 doi: 10.3892/ol.2017.5751 – ident: e_1_2_11_44_1 doi: 10.1007/s00403-009-0994-y – ident: e_1_2_11_35_1 doi: 10.3389/fphar.2019.00123 – ident: e_1_2_11_38_1 doi: 10.1002/cam4.2393 – ident: e_1_2_11_69_1 doi: 10.1016/j.ccr.2014.03.010 – ident: e_1_2_11_25_1 doi: 10.1016/j.biopha.2018.02.011 – ident: e_1_2_11_56_1 doi: 10.1002/path.5257 – ident: e_1_2_11_34_1 doi: 10.1038/nchembio.118 – ident: e_1_2_11_49_1 doi: 10.1007/s00401-002-0661-2 – ident: e_1_2_11_24_1 doi: 10.1111/eos.12387 – ident: e_1_2_11_60_1 doi: 10.3390/ijms221810030 – ident: e_1_2_11_14_1 doi: 10.3389/fbioe.2021.600579 – ident: e_1_2_11_46_1 doi: 10.1016/S0002-9440(10)62256-0 – ident: e_1_2_11_76_1 doi: 10.1080/21655979.2021.1955177 – ident: e_1_2_11_52_1 doi: 10.1186/s13058-021-01478-9 – ident: e_1_2_11_5_1 doi: 10.1021/jm401248x – ident: e_1_2_11_6_1 doi: 10.3109/02652040903079526 – ident: e_1_2_11_23_1 doi: 10.1002/jcb.27654 – ident: e_1_2_11_9_1 doi: 10.1016/j.ijpharm.2013.03.019 – ident: e_1_2_11_30_1 doi: 10.1248/bpb.b19-00839 – ident: e_1_2_11_33_1 doi: 10.1038/nbt1007-1110 – ident: e_1_2_11_39_1 doi: 10.3390/ijms19082378 – ident: e_1_2_11_42_1 doi: 10.1039/C5NP00005J – ident: e_1_2_11_10_1 doi: 10.1088/0957-4484/17/23/018 – ident: e_1_2_11_31_1 doi: 10.7314/APJCP.2014.15.15.6437 – volume: 112 start-page: 418 year: 2021 ident: e_1_2_11_74_1 article-title: TGF‐beta‐induced cell cycle arrest is associated with increased migration and metastasis of oral squamous carcinoma cells publication-title: Cancer Sci – ident: e_1_2_11_67_1 doi: 10.1016/j.bbadis.2021.166290 – ident: e_1_2_11_55_1 doi: 10.1016/j.biopha.2019.109667 – ident: e_1_2_11_79_1 doi: 10.1053/j.gastro.2021.04.064 – volume: 11 start-page: 731 issue: 8 year: 2021 ident: e_1_2_11_64_1 article-title: Differential expression of the androgen receptor, splice variants and relaxin 2 in renal cancer publication-title: Life (Basel) – ident: e_1_2_11_27_1 doi: 10.18632/oncotarget.21880 – ident: e_1_2_11_73_1 doi: 10.1158/1541-7786.MCR-18-0558 – ident: e_1_2_11_22_1 doi: 10.5114/aoms.2018.77068 – ident: e_1_2_11_37_1 doi: 10.3892/etm.2010.145 – ident: e_1_2_11_45_1 doi: 10.1016/j.cyto.2009.08.002 – ident: e_1_2_11_48_1 doi: 10.1016/j.cellsig.2007.12.003 – ident: e_1_2_11_13_1 doi: 10.1016/j.jsps.2017.04.037 – ident: e_1_2_11_43_1 doi: 10.1016/j.cyto.2020.155066 – ident: e_1_2_11_65_1 doi: 10.1007/s10585-014-9679-9 – ident: e_1_2_11_26_1 doi: 10.1155/2021/4340950 – ident: e_1_2_11_7_1 doi: 10.1080/10837450.2021.1982966 – ident: e_1_2_11_36_1 doi: 10.3390/md14090166 – ident: e_1_2_11_3_1 doi: 10.2147/OTT.S262022 – ident: e_1_2_11_11_1 doi: 10.1007/s10517-021-05324-y – ident: e_1_2_11_20_1 doi: 10.1097/CAD.0000000000000797 – ident: e_1_2_11_28_1 doi: 10.3892/ol.2017.6421 – ident: e_1_2_11_54_1 doi: 10.3390/ijms22147748 – ident: e_1_2_11_41_1 doi: 10.3390/ijms21197186 – volume: 11 start-page: 642 issue: 7 year: 2021 ident: e_1_2_11_59_1 article-title: High androgen receptor mRNA expression is associated with improved outcome in patients with high‐risk non‐muscle‐invasive bladder cancer publication-title: Life (Basel) – ident: e_1_2_11_81_1 doi: 10.1073/pnas.080583397 – volume: 16 start-page: 4859 issue: 6 year: 2018 ident: e_1_2_11_18_1 article-title: Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl‐2 publication-title: Exp Ther Med – ident: e_1_2_11_53_1 doi: 10.1001/jamaoncol.2016.4975 – ident: e_1_2_11_15_1 doi: 10.1093/abbs/gmz071 – ident: e_1_2_11_75_1 doi: 10.1038/s41419-021-04177-7 – ident: e_1_2_11_32_1 doi: 10.3892/ijo.2016.3479 – ident: e_1_2_11_40_1 doi: 10.3109/10428194.2015.1061127 – ident: e_1_2_11_12_1 doi: 10.1016/j.bbrc.2019.04.011 – ident: e_1_2_11_47_1 doi: 10.1016/j.canlet.2013.11.019 – ident: e_1_2_11_78_1 doi: 10.1111/j.1755-148X.2008.00450.x – ident: e_1_2_11_63_1 doi: 10.1016/j.jhep.2021.06.016 – ident: e_1_2_11_61_1 doi: 10.1200/JCO.21.01983 |
SSID | ssj0036139 |
Score | 2.6010568 |
Snippet | Statistics provided by GLOBOCAN list gastric cancer as the sixth most common, with a mortality ranking of third highest for the year 2020. In China, a herb... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2661 |
SubjectTerms | Androgen receptors Antibodies Apoptosis Cell morphology Cell proliferation Cells Cytology DNA fragmentation Gastric cancer Gastrointestinal tract Herbs Interdisciplinary subjects Medical research Morphology Original Pharmacology Proteins R&D Research & development Research methodology Signal transduction Statistical analysis Transforming growth factor-b Tumor necrosis factor-α |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3PT9swFLZGp0lcpv0CuhVktF12ME3i_DxNE1pBO8BhReotcvxsqETT0LTa-j_sj957ThpWQJxysKVEfrbf9-wv38fYFy8NibPoCQiKWISk3pr5WgvrhwkWRFp71ql9XsTnV-HPSTRpD9zqlla52RPdRg1zTWfkwyCNZeDRrdG36k6QaxTdrrYWGjvsJUmXEaUrmXQFl8RUlbWSpI69o2ezE58u2raT0CNk-ZAg-V_GGb1hr1uoyL83sX3LXpjyHXvVmEeu37O_l4sp0GEqr1eVo7Oaml8r8uHQXFMwF_zX2alIMBdzOp_nFTn0WNPEnBdr3tDAMXlxhIF8fDES7tfboSIVA5xZHLdDU2FVPhyfjURhlooT30M5HW9OZsa_1ZqrP9P6A7sa_RifnovWW0FoLOGWwvgQmsgWkKhAQgJa2tQYFUkTFbEJwIAsNMQaUxdEgA8cfIAQsTjiRR8yucd65bw0B4wH0vhRohEnWEB4l2UWbBYq6yVW-kqFffZ1M9i5boXHyf_iNu8KEAxM7gLTZ5-7vlUjt_Fkr8EmZnm75Or8foL02XHXjIuFRliVZr6iPiT3R6i1z_abEHevkYSl0hQ_N90KfteBhLi3W8rpjRPk9klkB3HTx-e_6xPbJbP6hqE2YL3lYmUOEdIsiyM3b_8BdMf7Ow priority: 102 providerName: ProQuest |
Title | Oridonin suppresses gastric cancer SGC ‐7901 cell proliferation by targeting the TNF ‐alpha/androgen receptor/ TGF ‐beta signalling pathway axis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37431884 https://www.proquest.com/docview/2863206842 https://www.proquest.com/docview/2854430519 https://pubmed.ncbi.nlm.nih.gov/PMC10494293 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtRAEC1lESgXFNY4hFEjuHBwYrvb2wFFIcokQmJAMEYjLla7FzJS4kxmEZkbn4D4RL6EKm9iICdOPnRZtrqqXa-6y-8BvPQSQT2LnquDInIFsbemvlKu9UWMBZFSnq3YPgfRWSbejsLRGrT6nc0Ezm4t7UhPKpte7N9cLw9xwb_uunLU5eW-Twdo67CJGSmmBfpOdKcJHFNWWvGmIprEEE4amtLVe7fgLqd0miRiNUf9Azz_7p_8IyH1t-FegyTZUe36-7Bmygdwp9aWXD6En--nY017rWy2mFTdrmbGvkqS6VBMka-n7NPp8a_vP2JM1ow28NmEJHysqYOCFUtW94ljdmOIE9lw0Efz6u_cA0lEBxh8DL-YZoKF-8HwlEYLM5eMmkJkRfbNSPH4m1wyeTOePYKsfzI8PnMbAQZXYZ03d42vhQltoWMZcB1rxW1ijAy5CYvIBNpoXigdKcxvOtR44YGntUDAjqDS1yl_DBvlVWl2gAXc-GGsEExYjRgwTa22qZDWiy33pRQOvGqnPFcNOzmJZFzkXZWCnsorTznworOd1Jwct1rttZ7L27DKgyTCd6SzRweed8O4omiWZWmuFmRDnIAEbR14Uju6e0wbIQ4kKyHQGRBb9-pIOT6vWLt9YuJBcLX7_7c-hS1Su69b3PZgYz5dmGeIieZFD9bjUdyDzaPP2ZcMr29OBh8-9qodhl61GH4Ds4kXZA |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VqRBcEG8CBRYBBw5LbK-fB4SgNE1pCQhSqTd3vY82EnVM4qjkP_Bb-I3M-AUBxK0nH3alXe3Mznzjmf0G4KkT-1Sz6HDtZSH3ib01cZXi1vUjDIiUcmzF9jkOR4f-u6PgaAN-tG9hqKyytYmVodYzRf_IB14cCs-hrNGr4iunrlGUXW1baNRqsW9W5xiyLV7uvUX5PvO84c5ke8SbrgJcYfBScuNq3wQ205H0hI60EjY2RgbCBFloPG20yJQOFRptHWj84LJa-4hCESm5msiX0ORv-gJDmR5svtkZf_zU2n6BzjFpSFCreiF1dvbCpdTeutv7C8v-WZL5m48bXoOrDThlr2ttug4bJr8Bl-p2laub8P3DfKrp9y1bLIuqgNYs2Imkzh-KKVKfOfu8u80j9P6MMgKsoJ5A1tRaxrIVqwvP0V0yBJ5sMh7y6rHvQBJvAuoyQwNsinI2H0x2hzwzpWRUYSIr5nBG7ZPP5YrJb9PFLTi8kHO_Db18lpu7wDxh3CBSiEysRkCZJFbbxJfWiaxwpfT78Lw97FQ1VOfUceNL2oU8KJi0EkwfnnRzi5rg45-ztlqZpc0lX6S_VLIPj7thvJ50wjI3syXNIYJBwsl9uFOLuFtGEHqLY9xuvCb8bgJRf6-P5NPTigLcJVofRGr3_r-vR3B5NHl_kB7sjffvwxUPAVpdH7cFvXK-NA8QUJXZw0aLGRxf9MX5CftcO5k |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLWqIhAbxJuBAkbAgoWZOM5zgRBqSVuKBiSm0uyC4wcdqc2ESUZl_oEv4uu413nAAGLXVRaxFMv34XPj43MJeeYlAXIWPab9ImIBqremXClmeRBDQaSUZ53a5yQ6OA7ezcLZFvnR34VBWmWfE12i1guF_8jHfhIJ38NTo7HtaBEf97LX1VeGHaTwpLVvp9G6yJFZn0P5Vr863ANbP_f97O1094B1HQaYgkKmYYbrwIS20LH0hY61EjYxRobChEVkfG20KJSOFCRwHWp4wBS0DgCRAmriGoWYIP1fikXIMcbi2VDsCdgm004O1TGH1NnZS46HfJsb4F-o9k9y5m-7XXadXOtgKn3T-tUNsmXKm-Ry27hyfYt8_7Cca_yRS-tV5ai0pqZfJPYAUVShIy3pp_1dFgMOoHg2QCvsDmRN62-0WNOWgg4bJwUISqeTjLlrv2OJCgrg1RRSsamaxXI83c9YYRpJkWsinYY4xUbK53JN5bd5fZscX8iq3yHb5aI09wj1heFhrACjWA3QMk2ttmkgrRdbwaUMRuRFv9i56kTPsffGaT4UP2CY3BlmRJ4OY6tW6uOfo3Z6m-VduNf5L-cckSfDawhUXGFZmsUKx6DUICLmEbnbmnj4jEAclyQw3WTD-MMAFAHffFPOT5wYOEeBH8Bs9_8_r8fkCoRL_v5wcvSAXPUBqbVEuR2y3SxX5iEgq6Z45FyYks8XHTM_Acp5Pmk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oridonin+suppresses+gastric+cancer+SGC%E2%80%907901+cell+proliferation+by+targeting+the+TNF%E2%80%90alpha%2Fandrogen+receptor%2FTGF%E2%80%90beta+signalling+pathway+axis&rft.jtitle=Journal+of+cellular+and+molecular+medicine&rft.au=Gao%2C+Shiyong&rft.au=Tan%2C+Huixin&rft.au=Li%2C+Dan&rft.date=2023-09-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=1582-1838&rft.eissn=1582-4934&rft.volume=27&rft.issue=18&rft.spage=2661&rft.epage=2674&rft_id=info:doi/10.1111%2Fjcmm.17841&rft_id=info%3Apmid%2F37431884&rft.externalDocID=PMC10494293 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1582-1838&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1582-1838&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1582-1838&client=summon |